A Fluoroquinolone Resistance Protein from Mycobacterium tuberculosis That Mimics DNA

Fluoroquinolones are gaining increasing importance in the treatment of tuberculosis. The expression of MfpA, a member of the pentapeptide repeat family of proteins from Mycobacterium tuberculosis, causes resistance to ciprofloxacin and sparfloxacin. This protein binds to DNA gyrase and inhibits its activity. Its three-dimensional structure reveals a fold, which we have named the right-handed quadrilateral β helix, that exhibits size, shape, and electrostatic similarity to B-form DNA. This represents a form of DNA mimicry and explains both its inhibitory effect on DNA gyrase and fluoroquinolone resistance resulting from the protein's expression in vivo.

[1]  S. Burley,et al.  Crystal structure of the Escherichia coli SbmC protein that protects cells from the DNA replication inhibitor microcin B17 , 2002, Proteins.

[2]  Anthony Maxwell,et al.  Crystal structure of the breakage–reunion domain of DNA gyrase , 1997, Nature.

[3]  C. Montero,et al.  Intrinsic Resistance of Mycobacteriumsmegmatis to Fluoroquinolones May Be Influenced by New Pentapeptide Protein MfpA , 2001, Antimicrobial Agents and Chemotherapy.

[4]  F. Hanaoka,et al.  Characterization of the Interaction between DNA Gyrase Inhibitor and DNA Gyrase of Escherichia coli * , 2002, The Journal of Biological Chemistry.

[5]  A. Telenti,et al.  Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations , 1994, Antimicrobial Agents and Chemotherapy.

[6]  R. Chaisson,et al.  Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. , 2004, American journal of respiratory and critical care medicine.

[7]  B. Barrell,et al.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.

[8]  G. Jacoby,et al.  Mechanism of plasmid-mediated quinolone resistance , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Orban,et al.  Solution structure of the highly acidic protein HI1450 from Haemophilus influenzae, a putative double‐stranded DNA mimic , 2003, Proteins.

[10]  A G Murzin,et al.  Structure and distribution of pentapeptide repeats in bacteria , 1998, Protein science : a publication of the Protein Society.

[11]  V. Jarlier,et al.  Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. , 1994, The Journal of infectious diseases.

[12]  F. Daschner,et al.  Plasmid-Mediated Quinolone Resistance in Isolates Obtained in German Intensive Care Units , 2005, Antimicrobial Agents and Chemotherapy.

[13]  V. Jarlier,et al.  Correlation between Quinolone Susceptibility Patterns and Sequences in the A and B Subunits of DNA Gyrase in Mycobacteria , 1998, Antimicrobial Agents and Chemotherapy.

[14]  C. Walsh,et al.  The antibiotic microcin B17 is a DNA gyrase poison: characterisation of the mode of inhibition. , 2001, Journal of molecular biology.

[15]  Thomas M. Shinnick,et al.  Microarray Analysis of the Mycobacterium tuberculosis Transcriptional Response to the Acidic Conditions Found in Phagosomes , 2002, Journal of bacteriology.

[16]  D. Maher,et al.  Guidelines for the Management of Drug-resistant Tuberculosis , 1997 .

[17]  N. Lounis,et al.  In Vitro and In Vivo Activities of Moxifloxacin and Clinafloxacin against Mycobacterium tuberculosis , 1998, Antimicrobial Agents and Chemotherapy.

[18]  P. Taylor,et al.  Structure of Ocr from bacteriophage T7, a protein that mimics B-form DNA. , 2002, Molecular cell.

[19]  F. Young.  Biochemistry , 1955, The Indian Medical Gazette.

[20]  A. Maxwell,et al.  The Action of the Bacterial Toxin Microcin B17 , 2003, Journal of Biological Chemistry.

[21]  T. Frieden,et al.  Emergence of fluoroquinolone-resistant tuberculosis in New York City , 1995, The Lancet.

[22]  A. Maxwell,et al.  A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex , 1993, Antimicrobial Agents and Chemotherapy.

[23]  G. Jacoby,et al.  Prevalence of Plasmid-Mediated Quinolone Resistance , 2003, Antimicrobial Agents and Chemotherapy.

[24]  K. Sakae,et al.  Cloning of a Novel Gene for Quinolone Resistance from a Transferable Plasmid in Shigella flexneri 2b , 2005, Antimicrobial Agents and Chemotherapy.

[25]  J. Musser,et al.  Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. , 1996, The Journal of infectious diseases.

[26]  R. Kolter,et al.  The export of the DNA replication inhibitor Microcin B17 provides immunity for the host cell. , 1988, The EMBO journal.

[27]  G. Jacoby,et al.  Interaction of the Plasmid-Encoded Quinolone Resistance Protein Qnr with Escherichia coli DNA Gyrase , 2005, Antimicrobial Agents and Chemotherapy.

[28]  V. Jarlier,et al.  Mycobacterium tuberculosis DNA Gyrase: Interaction with Quinolones and Correlation with Antimycobacterial Drug Activity , 2004, Antimicrobial Agents and Chemotherapy.

[29]  L. Kay,et al.  Solution Structure of a TBP–TAFII230 Complex Protein Mimicry of the Minor Groove Surface of the TATA Box Unwound by TBP , 1998, Cell.

[30]  E. Rubin,et al.  Genes required for mycobacterial growth defined by high density mutagenesis , 2003, Molecular microbiology.

[31]  K. Drlica,et al.  Fluoroquinolones: action and resistance. , 2003, Current topics in medicinal chemistry.